- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05172349
Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers
August 2, 2022 updated by: TBF Genie Tissulaire
Pilote Study of the Use of a Double Amniotic Membrane Inserted in a Ring of Umbilical Vessels With Wharton's Jelly, Tissues Treated by the AMTRIX Process, in the Treatment of Trophic Ulcers
The purpose of this open, multicenter pilot trial is to assess the impact of the use of an amniotic membrane on the healing of a persistent epithelial lesion or of a corneal ulcer.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 18 and 80 years old
- Stage 2 (persistent epithelial lesion : LEP) or stage 3 (corneal ulcer) trophic ulcer affecting only one eye. Patient whose contralateral eye is affected by stage 1 neurotrophic keratitis may also be included
- Two or more weeks old LEP or corneal ulcer refractory to one or more conventional nonsurgical therapies
- Absence of objective evidence of improvement of the epithelial ulceration or corneal ulcer within 2 weeks prior to study inclusion
- Failure of amniotic membrane treatment of the trophic ulcer: failure by absence of healing a few day after overlay treatment or 15 days after inlay grafting
- Patient able to understand French language
- Informed and consenting patient
- Patient affiliated to a social security system or beneficiary of such a system
Exclusion Criteria:
- Pregnant or breastfeeding patient or without contraception for non-menopausal women
- Active infectious ulcer
- Preperforating ulcer or ulcer that has reached the posterior 1/3 of the storm
- Allergy to Oxybuprocaine or Tetracaine eye drops, to ester type local anesthetics and to fluorescein
- Current contact lens wear, including scleral lenses
- NSAID eye drops and any drops containing preservatives
- Antibiotic, anti-viral, anti-parasitic eye drops
- Patients with identified causes of the ulcer for which medical treatment without preservatives or other healing treatment is beneficial
- Ocular surgery for other pathology than the trophic ulcer in the 3 months preceding the inclusion in the study
- Ophthalmologic pathology requiring daily eye drops
- Monophtalmic patients
- Persons deprived of liberty by a judicial or administrative decision
- Adults who are subject to a legal protection measure or who are unable to express their consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LV-Visio-AMTRIX
Sutureless amniotic membrane supported by a biological ring positioned by the investigator during patients' hospital visits.
|
Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Largest diameter of persistent epithelial lesion area or corneal ulcer under 0.5 mm
Time Frame: 15 days
|
Diameter assessed by centralized reading on photograph after fluorescein test
|
15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recovery of the visual acuity evaluated by Monoyer chart
Time Frame: 30 days, 45 days
|
30 days, 45 days
|
|
Stable or decreased score for inflammatory and clinical signs of the ocular surface
Time Frame: 2 days, 4 days, 7 days, 10 days, 15 days, 30 days, 45 days
|
Composite score for inflammatory and clinical signs of the ocular surface on 66 points.
Duration and intensity are evaluated for secretion, dry eyes, tearing, foreign body sensation, fluctuating vision, photophobia, burning sensation and lids edema.
Duration is evaluated from a scale from 0: never to 4: all the time.
Intensity is evaluated from a scale from 0: slight to 2: severe.
Localization and intensity are evaluated for conjunctival edema, conjunctival redness and neovascularization.
Localization is evaluated on a scale from 0: no reaction to 4: reaction present in the whole eye.
|
2 days, 4 days, 7 days, 10 days, 15 days, 30 days, 45 days
|
Stabilisation or decrease of pain evaluated on visual analog scale
Time Frame: 2 days, 4 days, 7 days, 10 days, 15 days, 30 days, 45 days
|
VAS on 10 points from 0: no pain to 10: worst imaginable pain
|
2 days, 4 days, 7 days, 10 days, 15 days, 30 days, 45 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2022
Primary Completion (Anticipated)
September 1, 2022
Study Completion (Anticipated)
September 1, 2022
Study Registration Dates
First Submitted
December 7, 2021
First Submitted That Met QC Criteria
December 27, 2021
First Posted (Actual)
December 29, 2021
Study Record Updates
Last Update Posted (Actual)
August 5, 2022
Last Update Submitted That Met QC Criteria
August 2, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L-Visio-AMTRIX-TBF4
- IDRCB (Registry Identifier: 2022-A02601-42)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Ulcer
-
University of ArkansasTerminatedBacterial Corneal UlcerUnited States
-
Sight Medical Doctors PLLCDompé, US, Inc.RecruitingNeurotrophic Keratitis | Neurotrophic Ulcer | Neurotrophic Corneal Ulcer | Neurotrophic KeratoconjunctivitisUnited States
-
Aravind Eye Care SystemUnknownMycotic Corneal UlcerIndia
-
Minia UniversityCompleted
-
Alaa GamalAl-Azhar UniversityCompleted
-
Mahidol UniversityTerminated
-
Peschke GmbHRecruitingKeratitis | Corneal UlcerUnited States
-
Aravind Eye Care SystemProctor FoundationUnknownCorneal Ulcer
-
Shaanxi Aierfu Activtissue EngineeringSouthwest Hospital, China; West China Hospital; Beijing Tongren Hospital; Henan... and other collaboratorsUnknown
Clinical Trials on LV-Visio-AMTRIX
-
TBF Genie TissulaireTerminated
-
TBF Genie TissulaireTerminated
-
TBF Genie TissulaireTerminatedAstigmatism | Myopia | HypermetropiaFrance
-
University Hospital, Strasbourg, FranceETHNODYNECompleted
-
University Hospital, BordeauxCompletedStroke | Cerebrovascular Disorders | Stroke, Ischemic | Stroke, AcuteFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Guy's and St Thomas' NHS Foundation TrustUnknown
-
Baylor Research InstituteMedtronicTerminatedCongestive Heart FailureUnited States
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Failure | Indications for Lead RemovalUnited States, Canada